歌礼制药宣布启动ASC30与ASC39固定剂量复方制剂临床开发,每日一次口服小分子GLP-1R激动剂联合胰淀素受体激动剂

美股速递
Apr 07

歌礼制药近日宣布,将正式推进其创新复方制剂ASC30与ASC39的临床开发计划。该固定剂量组合包含每日一次口服的小分子GLP-1受体激动剂ASC30,以及每日一次口服的小分子胰淀素选择性受体激动剂ASC39。这一双靶点疗法旨在通过协同作用机制提升代谢类疾病的治疗效果,标志着公司在代谢疾病领域创新药研发的重要进展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10